This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Evans, S. M. Articles by Koch, C. J. Search for Related Content PubMed PubMed Citation Articles by Evans, S. M. Articles by Koch, C. J.

2-Nitroimidazole (EF5) Binding Predicts Radiation Resistance in Individual 9L s.c. Tumors¹

Schools of Veterinary Medicine (Clinical Studies) [S. M. E.] and Medicine (Radiation Oncology) [W. T. J., B. J., C. J. K.], University of Pennsylvania, Philadelphia, Pennsylvania 19104, and Cancer Center, University of Rochester, Rochester, New York 14620 [E. M. L.]

The presence of hypoxic tumor cells is known to be an important cause of radiation treatment resistance in vivo. The ability to predict the presence and extent of hypoxic cells in individual tumors would allow the addition of specific "antihypoxia"-based treatment regimes. Hypoxia can be monitored by measuring the binding of 2-nitroimidazoles. We have tested the hypothesis that binding of EF5, a fluorinated derivative of the 2-nitroimidazole, Etanidazole, can predict radioresistance in individual tumors. Fischer rats bearing 9L s.c. tumors were given injections i.v. with EF5 3 h before irradiation and tumor harvest. Tumor cells were dissociated for flow cytometric analysis and plating efficiency studies. EF5 binding was detected via monoclonal antibodies conjugated to the orange emitting dye, Cy3. In air breathing rats, for a given radiation dose, a large amount of variation in plating efficiency was seen. However, there was minimal variability of the plating efficiency for tumors irradiated in euthanized animals (hypoxic tumors; correlation coefficient for the fitted curve = 0.93) and in cells dissociated from tumors and irradiated in suspension (correlation coefficient for the fitted curve = 0.99), suggesting that varying sensitivity to the cell disaggregation technique was not responsible. In contrast, a good correlation between the relative radiation resistance or hypoxic survival and EF5 binding of "moderately" hypoxic cells in air breathing rats was identified using these techniques. In these 9L s.c. tumors, intertumor variation in oxygenation accounted for most of the range in individual tumor radiation response, and this was found to be independent of tumor size. This study provides evidence for the application of EF5 binding with monoclonal antibody detection as an in vivo predictive assay of individual tumor hypoxia and resultant therapy resistance.

¹ This work was supported by NIH Grants CA-56679 (S. M. E., C. J. K.) and CA-62331 (S. M. E.) and the Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania.

² To whom requests for reprints should be addressed, at University of Pennsylvania, School of Veterinary Medicine, 3850 Spruce Street, Philadelphia, PA 19104.

Received 7/12/95. Accepted 11/13/95.

This article has been cited by other articles:

				D. A. Murphy, S. Makonnen, W. Lassoued, M. D. Feldman, C. Carter, and W. M.F. Lee Inhibition of Tumor Endothelial ERK Activation, Angiogenesis, and Tumor Growth by Sorafenib (BAY43-9006) Am. J. Pathol., November 1, 2006; 169(5): 1875 - 1885. [Abstract] [Full Text] [PDF]

				N. Pore, A. K. Gupta, G. J. Cerniglia, Z. Jiang, E. J. Bernhard, S. M. Evans, C. J. Koch, S. M. Hahn, and A. Maity Nelfinavir Down-regulates Hypoxia-Inducible Factor 1{alpha} and VEGF Expression and Increases Tumor Oxygenation: Implications for Radiotherapy. Cancer Res., September 15, 2006; 66(18): 9252 - 9259. [Abstract] [Full Text] [PDF]

				S.-M. Eschmann, F. Paulsen, M. Reimold, H. Dittmann, S. Welz, G. Reischl, H.-J. Machulla, and R. Bares Prognostic Impact of Hypoxia Imaging with 18F-Misonidazole PET in Non-Small Cell Lung Cancer and Head and Neck Cancer Before Radiotherapy J. Nucl. Med., February 1, 2005; 46(2): 253 - 260. [Abstract] [Full Text] [PDF]

				S. M. Evans, K. D. Judy, I. Dunphy, W. T. Jenkins, W.-T. Hwang, P. T. Nelson, R. A. Lustig, K. Jenkins, D. P. Magarelli, S. M. Hahn, et al. Hypoxia Is Important in the Biology and Aggression of Human Glial Brain Tumors Clin. Cancer Res., December 15, 2004; 10(24): 8177 - 8184. [Abstract] [Full Text] [PDF]

				K. L. Bennewith and R. E. Durand Quantifying Transient Hypoxia in Human Tumor Xenografts by Flow Cytometry Cancer Res., September 1, 2004; 64(17): 6183 - 6189. [Abstract] [Full Text] [PDF]

				T. M. Busch, S. M. Hahn, E. P. Wileyto, C. J. Koch, D. L. Fraker, P. Zhang, M. Putt, K. Gleason, D. B. Shin, M. J. Emanuele, et al. Hypoxia and Photofrin Uptake in the Intraperitoneal Carcinomatosis and Sarcomatosis of Photodynamic Therapy Patients Clin. Cancer Res., July 15, 2004; 10(14): 4630 - 4638. [Abstract] [Full Text] [PDF]

				S. M. Evans, K. D. Judy, I. Dunphy, W. T. Jenkins, P. T. Nelson, R. Collins, E. P. Wileyto, K. Jenkins, S. M. Hahn, C. W. Stevens, et al. Comparative Measurements of Hypoxia in Human Brain Tumors Using Needle Electrodes and EF5 Binding Cancer Res., March 1, 2004; 64(5): 1886 - 1892. [Abstract] [Full Text] [PDF]

				T. N. Seagroves, D. Hadsell, J. McManaman, C. Palmer, D. Liao, W. McNulty, B. Welm, K.-U. Wagner, M. Neville, and R. S. Johnson HIF1{alpha} is a critical regulator of secretory differentiation and activation, but not vascular expansion, in the mouse mammary gland Development, April 15, 2003; 130(8): 1713 - 1724. [Abstract] [Full Text] [PDF]

				C. J. Koch, P. R. Oprysko, A. L. Shuman, W. T. Jenkins, G. Brandt, and S. M. Evans Radiosensitization of Hypoxic Tumor Cells by Dodecafluoropentane: A Gas-Phase Perfluorochemical Emulsion Cancer Res., July 1, 2002; 62(13): 3626 - 3629. [Abstract] [Full Text] [PDF]

				M. Hockel and P. Vaupel Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects J Natl Cancer Inst, February 21, 2001; 93(4): 266 - 276. [Abstract] [Full Text] [PDF]

				K. R. Laderoute, R. M. Alarcon, M. D. Brody, J. M. Calaoagan, E. Y. Chen, A. M. Knapp, Z. Yun, N. C. Denko, and A. J. Giaccia Opposing Effects of Hypoxia on Expression of the Angiogenic Inhibitor Thrombospondin 1 and the Angiogenic Inducer Vascular Endothelial Growth Factor Clin. Cancer Res., July 1, 2000; 6(7): 2941 - 2950. [Abstract] [Full Text]

				M. S. Gee, C. J. Koch, S. M. Evans, W. T. Jenkins, C. H. Pletcher Jr., J. S. Moore, H. K. Koblish, J. Lee, E. M. Lord, G. Trinchieri, et al. Hypoxia-mediated Apoptosis from Angiogenesis Inhibition Underlies Tumor Control by Recombinant Interleukin 12 Cancer Res., October 1, 1999; 59(19): 4882 - 4889. [Abstract] [Full Text] [PDF]